F.A.R.O.G. FORUM, Vol. 5 No. 3

https://digitalcommons.library.umaine.edu/francoamericain_forum/1016/thumbnail.jp

F.A.R.O.G. FORUM, Vol. 5 No. 3

Contains a Supplement Littéraire.https://digitalcommons.library.umaine.edu/francoamericain_forum/1061/thumbnail.jp

F.A.R.O.G. FORUM, Vol. 5 No. 1

https://digitalcommons.library.umaine.edu/francoamericain_forum/1059/thumbnail.jp

F.A.R.O.G. FORUM, Vol. 5 No. 7

https://digitalcommons.library.umaine.edu/francoamericain_forum/1019/thumbnail.jp

F.A.R.O.G. FORUM, Vol. 5 No. 2

https://digitalcommons.library.umaine.edu/francoamericain_forum/1060/thumbnail.jp

F.A.R.O.G. FORUM, Vol. 6 No. 4

https://digitalcommons.library.umaine.edu/francoamericain_forum/1065/thumbnail.jp

Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates